Key result
Plasma renin test-guided drug treatment of hypertension may improve blood pressure control and reduce polypharmacy, highlighting the need for dedicated randomized clinical trials.
Why the study?
Does plasma renin test-guided drug treatment improve blood pressure control in hypertensive patients compared to standard empirical care?
Does plasma renin test-guided drug treatment improve blood pressure control in hypertensive patients compared to standard empirical care?
Answers are grounded in this paper and cite their sources.
Tailoring antihypertensive therapy based on plasma renin profiling may provide a more rational, effective, and safer approach to blood pressure control than current empirical guidelines, warranting definitive randomized clinical trials.
Centuries ago, fever was considered as a single condition or disease and it was treated by a single form of intervention, blood letting. Today, we treat hypertension in a similar way. No real distinction is made between the different pathophysiological types of hypertension. The mantra is—any antihypertensive drug can be used or “one size fits all”.1 The selection of the initial drug and any add-on drug is arbitrary. This is reflected in national and international guidelines that propose different initial treatments and then, when necessary, follow-up with different add-on drugs selected from a variety of antihypertensive drug types. As discussed below, the use of the pathophysiologically “wrong” antihypertensive drug typically leads to a smaller blood pressure reduction. It can also induce a paradoxical pressor response2–4 that contributes to increases in the prevalence of resistant hypertension. Similarly, initiating treatment with a fixed drug combination or treating patients arbitrarily with a large number of drugs is rarely an optimal approach.5 It is not science-based and the costs to patients and society are enormous and growing. A more rational approach would be to tailor treatment to the underlying subtype of hypertension. Low-renin, volume-dependent (V) hypertension ought to be treated with an anti-V drug and high-renin vasoconstriction (R) hypertension ought to be treated with an anti-R drug.6 Disengaging such long-standing medical practice is a major challenge. Status quo offers comfort to practitioners and to the guideline writers. Marketing campaigns are often inconsistent with best practices. Drug manufacturers typically worry about their sales figures so that they fear that anti-renin (anti-R) drugs will be prescribed only for hypertensives with high-plasma renin levels (R hypertension), thereby cutting the size of their target population and that anti-sodium volume (anti-V) drugs will be only prescribed for hypertensives with excess body-sodium-volume content (V hypertension). Regulators are known to be reactive rather than proactive and rarely revise regulations on their own. As a result, we have an arbitrary use of antihypertensive drugs leading to suboptimal treatment outcomes world-wide. Although plasma renin test-guided treatment of hypertension evolved in the early 1970's, its acceptance today is limited. A major factor has been difficulties in procuring the test and complicated conditions for patient preparation.6 But, today, plasma renin tests are available commercially, and standard blood draw conditions are used for blood collection. A 24-h urine collection is no longer required for renin profiling. So the issue has shifted toward the documentation of the hypothesis in general practice and to comparisons with treatments based on national guidelines. A major recent development was the realization that the test could also be used to guide the selection of add-on drugs.7 Many of the earlier studies that supported the hypothesis did not meet the rigor of properly designed clinical trials.8,9,10,11 Recently several trials, discussed below, have provided further evidence in support of the original renin hypothesis.7,12 More evidence is needed to document that the high medical and financial costs borne by patients and society for the treatment of hypertension can be reduced. In a first phase, multiple randomized clinical trials ought to evaluate the blood pressure effects of plasma renin-guided treatments compared to the standard step-up care.5 These findings could subsequently form the basis for a more optimal usage of antihypertensive drugs. The objective of this article is to describe the type of clinical trials that are needed. In a recent trial of 77 unsuccessfully treated hypertensive patients, 36% had low-ambulatory plasma renin activity (PRA) levels, 42% had medium renin, and 22% had high-plasma renin levels during treatment.7 They all were uncontrolled in spite of being treated with approximately three medications. Medications were added or subtracted after patients were randomized to either renin-test-guided treatment or to care by clinical hypertension specialists. Patients were followed until the end of the renin-guided treatment algorithm or until the clinician determined that appropriate therapeutic adjustments had been made. At the final visit, the number of antihypertensive drugs remained similar in the two groups. However, the systolic blood pressure (SBP) declined significantly more in the renin-guided group, a mean of −29.1 vs. a mean of −19.2 mm Hg (P = 0.03) and the proportion of patients who had their hypertension controlled was 74% vs. 59%, respectively. This trial showed that a plasma renin test during treatment could successfully guide follow-up drug selection for uncontrolled hypertensive patients who are already receiving antihypertensive drugs. Initiating treatment with the “wrong” type of drug, i.e., an anti-sodium-volume anti-V drug for R hypertension or an anti-vasoconstriction anti-R drug for V hypertension, can lead to a paradoxical pressor responses. Thus, Alderman et al.4 reported on the incidence of rises of SBP ≥10 mm Hg in 945 previously untreated hypertensives. Such paradoxical pressor responses occurred in 11% of 408 patients started on an anti-R drug and in 5% of 537 patients initiated on an anti-V drug. In plasma renin tertile analyses, the authors observed pressor responses in 17% of the lowest tertile given an anti-R drug, compared to 10% and 9% of the middle and high tertiles. For the anti-V drugs, all tertiles had close to 5% pressor responses. In the lowest plasma renin tertile, 35% of patients given anti-R drugs had on-treatment SBP ≥160 mm Hg compared to only 13% of such patients given anti-V drugs. The occurrence of pressor responses underscores the importance of selecting the right pathophysiological type of antihypertensive drug when initiating treatment. Turner et al.13 randomized 363 untreated hypertensive patients to either atenolol (an anti-R drug) followed by the addition of hydrochlorothiazide (an anti-V drug), as opposed to hydrochlorothiazide followed by the addition of atenolol. In both groups, there was a linear drop in SBP depending on plasma renin percentile; on atenolol monotherapy, SBP fell by a mean <2 mm Hg in those whose PRA level was in the lowest 10th percentile and SBP fell by a mean >10 mm Hg in those whose PRA level was above the 90th renin percentile. The reverse trend was seen in the groups whose treatment was initiated with hydrochlorothiazide monotherapy; a mean <6 mm Hg vs. a mean ≤2 mm Hg SBP reductions, respectively. Similar trends in SBP response were observed after washout in relation to the on-treatment PRA level with atenolol add-on and hydrochlorothiazide add-on therapy, respectively. These findings document that both the baseline and the on-treatment plasma renin levels have strong predictive values. There are many different types of hypertension—essential, renovascular, primary aldosteronism, Cushing's syndrome, pheochromocytoma, renal failure, and malignant. Irrespective of cause, the basic theory underlying the plasma renin test-guided system for blood pressure control is that, all long-term high blood pressure is ultimately sustained by an excess body sodium-volume content (V hypertension), or an excess plasma renin–angiotensin vasoconstriction (R hypertension) or both excess volume and vasoconstriction (V+R hypertension).14–16 A corollary of this concept is that all effective antihypertensive medications are either anti-V or anti-R.6 The physiological basis for the plasma renin-test-guided treatment of hypertension was developed by Laragh and coworkers over a lifetime of clinical research. It is described in an accompanying report.6 In the plasma renin-test-guided treatment system, a pretreatment PRA level is used to reveal the relative contributions of excess sodium-volume content or renin-dependent vasoconstriction in the individual patient. Patients with low PRA (<0.65 ng/ml/h) have V hypertension, whereas those with medium/high PRA (≥0.65 ng/ml/h) have varying degrees of R hypertension.6 Primary drug treatment is initiated with an anti-V drug in V hypertension, and with an anti-R drug in R hypertension. It is anticipated that about two-thirds of V patients and half of R patients will have their elevated blood pressure controlled long term with full-dose monotherapy. A follow-up PRA test is then used to determine why complete blood pressure control was not achieved with full-dose monotherapy and to guide the choice of follow-up drug.6 The reasons why blood pressure may not be fully controlled by the first drug are: inadequate volume depletion, inadequate blockade of the renin–angiotensin system, or the presence of both excess sodium-volume and excess vasoconstriction in the same patient: The V patient was insufficiently volume depleted (V+V patient). This patient will still have a low PRA (<0.65 ng/ml/h) and needs more natriuresis either by adding a 2nd anti-V drug or by switching to a different anti-V drug. The anti-V drug induced a reactive rise in PRA in the V patient and the higher PRA level is now helping to sustain the high blood pressure (V+R patient). PRA will have increased into the range of R patients, i.e., ≥0.65 ng/ml/h. This patient now needs an anti-R drug added to fully control the blood pressure. The R patient had V hypertension as well (R+V patient). The key to identifying this type of patient is to show that their renin–angiotensin system has either been effectively suppressed or successfully blocked in vivo. If the anti-R drug suppressed PRA levels (e.g., a β-blocker), PRA will now be in the low range (<0.65 ng/ml/h). But, if the anti-R drug was an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, a PRA level <6.5 ng/ml/h indicates effective blockade of the renin–angiotensin system because these drug types act in vivo to block the renin–angiotensin by ~90%. If the renin system is adequately blocked and BP is not controlled, an anti-V drug type is added to control the blood pressure.17 The anti-R drug caused large reactive increases in PRA levels that cannot be completely blocked by one anti-R drug (R+R patient). If PRA remains above 0.65 ng/ml/h while taking a renin-suppressing drug, or above 6.5 ng/ml/h while taking an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, a fraction of circulating renin–angiotensin remains active in vivo; such patients need two anti-R drugs.6 An alternative approach might be to liberalize the patient's dietary salt intake to restore enough volume to prevent reactive increases in PRA levels. As just described, the PRA test can be used to guide follow-up therapy for patients who are already taking one or more drugs but are unsuccessfully controlled. Treatment can begin by reducing the number of drugs to one anti-V and one anti-R drug and then, after 3 weeks, measuring the PRA level if blood pressure is not controlled. Then, two other facts should be taken into account: Anti-R drugs can increase the blood pressure of some V patients and make their blood pressure more difficult to control with additional drugs. Natriuretic anti-V drugs can make the blood pressure of some R patients difficult to control because they augment the increase in PRA level induced by anti-renin system drugs. Thus, if clinically indicated, it is useful to determine whether better blood pressure control is achieved by subtracting anti-R drugs from unsuccessfully controlled patients whose PRA levels are low, or subtracting anti-V drugs from unsuccessfully controlled patients whose PRA levels are high. Accordingly, the evidence to date strongly suggests that plasma renin test-guided selection of antihypertensive drugs could define a more efficient way of lowering elevated long-term blood pressure. However, additional clinical trials are needed to demonstrate the effectiveness of this approach in the general population. Therefore, we believe the time has come to design and conduct randomized clinical trials to evaluate the effectiveness and usefulness of a plasma renin test-guided strategy (i) for bringing more hypertensive subjects to established treatment goals and (ii) for reducing the number of drugs and the number of visits to achieve blood pressure control. Four different goals and four different study populations are proposed (Table 1): Trial I. Guiding initial and follow-up treatment strategies in untreated hypertensive patients. Trial II. Guiding follow-up drug subtractions and additions in hypertensive patients whose BP is uncontrolled on an anti-V + an anti-R drug combination. Trial III. Guiding drug subtractions and additions in hypertensive patients whose BP is uncontrolled on three or more antihypertensive drugs. Trial IV. Reducing medication burden in hypertensive patients whose BP is controlled on four or more drugs. The interventions for all four trials would be plasma renin test-guided according to Figures 1,2 and 3. The choice of control groups is a challenge. For trial I, we recommend that treatment is initiated with a fixed combination drug (anti-V drug + an anti-R). Trial II starts with this same combination at maximum dose. Then for both trials, step-up treatment(s) will be guided by a protocol based on national guidelines. This structured approach enables comparison to a “standard of care.” For trials III and IV, we recommend drug selection for the control group based on physician's choice. The primary outcome for trial I would be the proportion of patients at the treatment goal on ≤2 drugs. For trial II, it would be the proportion controlled at trial completion by the number of drugs. For trial III, it would be the proportion of patients at treatment goal at trial completion. For trial IV, it would be the average number of drugs per study group while still controlled. Secondary outcomes would include mean change in SBP at trial completion and the average number of drugs per study group. Trials III and IV would also consider the proportion of participants meeting the conventional definition of resistant hypertension. Additionally, trials I, II, and IV would also look at average reduction in cost of antihypertensive drugs. The treatment goal for all trials would be SBP ≤140/90 mm Hg for a treatment period of 6 months. Thus, for trial I, if the baseline SBP is 156 ± 12 mm Hg, and the proportion of participants at goal at trial completion is 80% in the renin-guided group and 50% in the control group, and α = 0.05 and power 80%, the total sample size would be around 80. For a smaller intervention effect (70%) the total sample size would be ~280. Similar calculations would have to be made for the trials II–IV. Some challenges in conducting the proposed trials are anticipated. Recruitment should not be a major problem since the sample sizes should be relatively small or in the low hundreds. The real challenge will be to keep the control groups adhering to the prespecified step-up protocol (trials I and II). The experience from trials with an open (unblinded) design is that physicians deviate from the established protocol and try to make their control treatment look better. For example, rather than following the step-up program that does not advocate subtracting any antihypertensive drugs except for reasons of side effect, they may switch subjects to another drug if the initial one does not cause a clear reduction in SBP. This problem emerged in the trial by Egan et al.7 in which clinical hypertension specialist care was used as control. To our knowledge, clinical hypertension specialists are not advised to test the effects of drug subtraction, yet the anti-R drug number fell in the low-renin control group and the anti-V drug number fell in the high-renin control group.7 The proposed trials focus on SBP control and would not be of sufficient scope to determine the effect of treatment on major cardiovascular events. The conventional wisdom is that the risk of events is linked to the actual blood pressure level. However, it is possible that the type of hypertension, V or R, may determine the type of cardiovascular complications. Recent findings by Gonzalez and coworkers18 have confirmed their earlier work that high-plasma levels of renin are independently related to the risks of acute myocardial infarction.19 Thus, R hypertension may well be associated with higher risks of myocardial infarction. This raises the question whether the type and rate of cardiovascular complications are the same for R and V hypertension when they are treated with drugs specifically targeted to the pathological defect. Observation studies and future clinical trials ought to address this potentially important clinical question. Outline of the four proposed randomized clinical trails Outline of the four proposed randomized clinical trails If the plasma renin test-guided treatment of hypertension hypothesis is confirmed in the proposed trials, one would expect the following actions: The national and international treatment guidelines for treatment would be revised accordingly. They would endorse using the plasma renin test to find out if a patient's high blood pressure is being sustained by excess salt (sodium-volume) or by excess renin–angiotensin vasoconstriction, or both, and then use that information to guide the addition or subtraction of anti-V or anti-R drug types. The regulatory agencies around the world would alter the currently approved indications for marketed and new antihypertensive drugs. The indication for anti-V drugs as first-line drugs would be limited to V hypertension and for anti-R drugs as first-line drugs to R hypertension. The selection of add-on drugs would depend on the treatment ambulatory plasma renin level. The reliance on PRA tests would require local hospitals and others to offer such analyses; it would encourage the medical testing industry to promote automated testing that, in turn, would likely further lower cost and reduce turn around time. It is essential that in this process standardization of the renin test be established. Practicing physicians and other healthcare providers would need opportunities to learn more about this treatment through continuing education programs. A major unknown would be how the pharmaceutical industry would react and behave. In conclusion, the current level of treatment and control of hypertension in the United States, ~50%, is unacceptably low.20 The use of polypharmacy is widespread5 and likely unnecessary. A concerted effort is required to improve this performance. We need a more rational, science-based approach to improve the situation. There is growing research evidence that plasma renin test-guided drug treatment leads to better control, often with fewer antihypertensive drugs. Further supportive evidence is needed to convince physicians, framers of treatment guidelines and regulators. Thus, the time is right to proceed with randomized clinical trials such as those advocated in this article. The author declared no conflict of interest.
No takes yet. Share an insight, caveat, or question.
C. D. Furberg (2011) conducted a review in Hypertension. Plasma renin test-guided drug treatment vs. Standard care was evaluated. Plasma renin test-guided drug treatment of hypertension may improve blood pressure control and reduce polypharmacy, highlighting the need for dedicated randomized clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: